Advertisement

Organisation › Details
Intercell AG (VSE: ICLL)
Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell’s vaccine to prevent Japanese Encephalitis is the Company’s first product on the market. The Company’s technology platform includes an antigen-discovery system and human anti-infective monoclonal antibody discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships, including with a number of pharmaceutical companies, with GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Romark. The Company’s pipeline of investigational products includes a Pseudomonas aeruginosa vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase I/II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), a vaccine candidate for Pneumococcus (Phase I) as well as a combination treatment approach for Hepatitis C (Phase II). A vaccine candidate against infections with C. difficile has entered Phase I clinical trials in 2010. In addition, further products focused on infectious diseases are in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol “ICLL” (U.S. level one ADR symbol “INRLY”). *
![]() |
Start | 1998-01-01 established |
![]() |
End | 2013-05-28 renamed |
Group | Valneva (Group) | |
Today | Valneva Austria GmbH | |
Successor | Intercell Austria AG | |
![]() |
Industry | vaccine |
![]() |
Person | Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring) |
Person 2 | Kandera, Reinhard (Hookipa Biotech 201704– CFO before Valneva CFO + Intercell CFO + Deutsche Bank AG) | |
![]() |
Region | Wien (Vienna) |
Country | Austria | |
Street | 3 Campus-Vienna-Biocenter | |
City | 1030 Wien | |
Tel | +43-1-20620-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2011-03-01) |
Currency | EUR | |
Annual sales | 35,665,000 (revenues (2012) 2012-12-31) | |
Profit | -25,337,000 (2012-12-31) | |
Cash | 44,933,000 (2012-12-31) | |
* Document for �About Section�: Intercell AG. (3/1/11). "Press Release: Intercell Announces Q4 and Preliminary Full Year 2010 Financial Results. Growing Revenues from Ixiaro/Jespect Sales – Significant Net Loss Due to One-time Non-cash Effects". Vienna. | ||
Record changed: 2017-04-01 |
Advertisement

More documents for Valneva (Group)
- [1] Valneva S.E.. (11/10/20). "Press Release: Valneva Announces Plans for Extraordinary General Meeting to Prepare for Potential US IPO". Saint-Herblain....
- [2] Valneva S.E.. (9/8/20). "Press Release: Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553". Saint-Herblain....
- [3] Valneva S.E.. (7/20/20). "Press Release: Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program". Saint-Herblain....
- [4] Valneva S.E.. (6/18/20). "Press Release: Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership". Saint-Herblain....
- [5] Valneva S.E.. (4/30/20). "Press Release: Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15". Saint-Herblain & New York, NY....
- [6] Valneva S.E.. (4/22/20). "Press Release: Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19". Saint-Herblain & Emeryville, CA....
- [7] Valneva S.E.. (2/3/20). "Press Release: Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed". Saint-Herblain....
- [8] Valneva S.E.. (1/14/20). "Press Release: US DoD Exercises Option on Ixiaro Supply Contract Bringing Total Value to $70 Million". Saint-Herblain....
- [9] Valneva S.E.. (1/9/20). "Press Release: Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Saint-Herblain....
- [10] Valneva S.E.. (12/20/19). "Press Release: Valneva Completes Delisting from the Vienna Stock Exchange". Saint-Herblain....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top